DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Denali Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.04+0.43 (+2.44%)
Close on Oct 19, 2026
- Market cap
- $3.38B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.38 (+8.28%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Denali Therapeutics Inc. reported revenue of $0 for fiscal 2025. Free cash flow was -$437.46M.
Revenue
$0
FY2025
Operating income
-$542.70M
TTM Q2 2026
Free cash flow
-$437.46M
TTM Q2 2026
EPS, diluted
-$2.84
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $3.38B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.05
- Dividend yield
- –
- Free cash flow yield
- -12.95%
Fundamentals
- Revenue
- $0
- Net income
- -$511.45M
- EPS, diluted
- -$2.84
- Free cash flow
- -$437.46M
- Book value per share
- $4.46
- Diluted shares
- 187M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$542.70M
Net income
-$511.45M
EPS, diluted
-$2.84
Free cash flow
-$437.46M
Reported periodTrailing twelve months